VIGENCELL INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,480 KRW | -4.17% |
|
-5.58% | -23.42% |
| 2023 | ViGenCell Inc.(KOSDAQ:A308080) dropped from S&P Global BMI Index | CI |
| 2023 | ViGenCell Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 3,47,946 | 1,35,323 | 1,12,120 |
| Enterprise Value (EV) 1 | 2,91,852 | 73,659 | 66,158 |
| P/E ratio | -24.3 x | -7.77 x | -6.24 x |
| Yield | - | - | - |
| Capitalization / Revenue | - | - | - |
| EV / Revenue | - | - | - |
| EV / EBITDA | -25.6 x | -4.82 x | -4.14 x |
| EV / FCF | - | -37,43,907 x | -69,50,561 x |
| FCF Yield | - | -0% | -0% |
| Price to Book | 3.32 x | 1.51 x | 1.57 x |
| Nbr of stocks (in thousands) | 18,884 | 19,006 | 19,166 |
| Reference price 2 | 18,425 | 7,120 | 5,850 |
| Announcement Date | 15/03/23 | 15/03/23 | 18/03/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales | - | - | - |
| EBITDA 1 | -11,417 | -15,296 | -15,987 |
| EBIT 1 | -13,136 | -18,214 | -20,084 |
| Operating Margin | - | - | - |
| Earnings before Tax (EBT) 1 | -11,114 | -17,393 | -17,875 |
| Net income 1 | -11,114 | -17,393 | -17,875 |
| Net margin | - | - | - |
| EPS 2 | -759.0 | -916.0 | -937.0 |
| Free Cash Flow | - | -19,674 | -9,518 |
| FCF margin | - | - | - |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 15/03/23 | 15/03/23 | 18/03/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | - | - | - |
| Net Cash position 1 | 56,093 | 61,664 | 45,962 |
| Leverage (Debt/EBITDA) | - | - | - |
| Free Cash Flow | - | -19,674 | -9,518 |
| ROE (net income / shareholders' equity) | - | -17.9% | -22.2% |
| ROA (Net income/ Total Assets) | - | -10.5% | -13.9% |
| Assets 1 | - | 1,65,285 | 1,28,463 |
| Book Value Per Share 2 | 5,554 | 4,717 | 3,729 |
| Cash Flow per Share 2 | 1,701 | 439.0 | 923.0 |
| Capex 1 | 11,522 | 13,654 | 976 |
| Capex / Sales | - | - | - |
| Announcement Date | 15/03/23 | 15/03/23 | 18/03/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -23.42% | 62.69M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- A308080 Stock
- Financials ViGenCell Inc.